uniQure N.V.

Research uniQure N.V. (QURE) on Bullrun: market cap USD 2.99B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerQURE
• ExchangeNASDAQ
• CountryNetherlands
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 2.99B
• Financial periodFY2025
• RevenueUSD 16.10M
• Revenue growth-40.6%
• Net income-USD 199.00M
• Free cash flow-USD 178.40M
• Gross margin89.5%

Valuation Snapshot

latest market cap is USD 2.99B.

About uniQure N.V.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease.

Frequently asked questions

What is uniQure N.V.'s market cap?

uniQure N.V.'s market capitalization is USD 2.99B.

What does uniQure N.V. do?

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding.